Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease
International Journal of Pharmaceutics, 283 (1-2), 4551
Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, glucose-dependent insulinotropic polypeptide agonists and other metabolic hormones for the treatment of chronic kidney disease
10.1016/j.jhep.2022.06.012 60 PfisterD.NezN
In contrast, a pooled analysis of clinical trials reporting separate CV events rates in patients with T2D and CKD did not find GLP1-RA to be associated with a reduction in composite CV event rates [76]
You stall less
US$ 21.23
US$ 22.57
US$ 22.87
US$ 21.94
